A Study of Replagal in Children and Adults With Fabry Disease in India

Fabry Disease Clinical Trial

Official title:

A Prospective, Open-label, Multicentre, Interventional, Single-arm, Phase IV Study to Evaluate the Safety and Efficacy of Agalsidase Alfa (r-DNA Origin) (Replagal™) in Indian Children and Adults With Fabry Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05067868
• Other study ID #: TAK-675-4008
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: November 1, 2022
• Est. completion date: November 30, 2024

Study information

• Verified date: March 2023
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5
• Est. completion date: November 30, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Male and female Replagal naïve participants (and who are not part of any other program at the time of study enrollment and during the study period) of any age with confirmed diagnosis of Fabry disease.

2. Participants who have documented confirmed diagnosis of Fabry disease based on proof of gene mutation: a-galactosidase A gene compatible with Fabry disease and/or a deficiency of a-galactosidase A (less than [<] 4.0 nanomol per milliliter per hour (nmol/mL/hour) in plasma or serum or <8 percent (%) of average mean normal in leukocytes and sequencing of GLA gene for females).

3. Participant must have any clinical manifestations of Fabry disease based on investigator's discretion.

4. Participant/legal authorized representative (LAR)/guardian must be able to understand and willing to give written informed consent before performing any study specific procedures and willing to adhere to protocol requirements.

5. Female participants of childbearing potential (example, nonsterilised, premenopausal female participants) must have a documented negative pregnancy test prior to administration of the first dose of Replagal in this study. In addition, all female participants of childbearing potential must use a medically accepted form of contraception throughout the study, that is, either a barrier method or hormonal contraceptive with norethindrone and ethinyl estradiol or similar active components.

6. Male participant who is nonsterilised and sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (example, condom with or without spermicide) from signing of informed consent throughout the duration of the study. Note: Female participants not of childbearing potential defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (example, defined as at least 1 year since last regular menses with an appropriate clinical profile [that is, age appropriate, history of vasomotor symptoms]).

Exclusion Criteria:

1. Participants who have received Replagal.

2. Participants with poorly controlled hypertension as per investigator's discretion.

3. Participants with chronic kidney disease (CKD) with estimated Glomerular Filtration rate less than 15 milliliter per minute (mL/min) /1.73 meter square (m^2) and who had/will have kidney transplantation or are currently on dialysis.

4. Participants with any serious hepatic disorder who had abnormal hepatic function test values at screening (when either alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level exceeded the value three times the upper limit of normal [ULN] and total bilirubin 1.5 times as high as the ULN); and deemed as clinically significant by investigator for hematology and biochemistry. These abnormal laboratory values could be discussed with medical monitor before excluding the participant.

5. If female, the participant is pregnant or lactating or intending to become pregnant before participating in this study, during the study; or intending to donate ova during such time period.

6. Participant/LAR/guardian is unable to understand the nature, scope, and possible consequences of the study.

7. Participant is unable to comply with the protocol, example, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the investigator.

8. If male, the participant intends to donate sperm during the course of this study.

9. Participants who had participated in any other investigational drug study within the past 4 weeks prior to screening.

10. Any participant deemed as unfit for this trial, as per investigator's clinical judgment.

Related Conditions & MeSH terms

• Fabry Disease

Intervention

Biological:
• Replagal
Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.

Locations

Country	Name	City	State
India	Rainbow Super Specialty Hospital	Hyderabad
India	J K Lone Hospital	Jaipur
India	Institute of Child Health	Kolkata
India	All India Institute of Medical Sciences (AIIMS)	New Delhi
India	Sir Gangaram Hospital	New Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical (study) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (study) product, whether or not related to the medicinal (study) product. An SAE is any untoward medical occurrence (whether considered to be related to study product or not) that at any dose results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality or birth defect, an important medical event.	From the start of study up to 53 weeks
Primary	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	AE is any unfavorable and unintended sign, symptom, or disease temporally associated with study or use of investigational drug product (IP), whether or not the AE is considered related to IP. TEAEs: AEs occurring or worsening at or after first dose of IP or ongoing at time of enrollment. SAE :untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. Severity: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.	From the study drug administration up to Week 53
Primary	Number of Participants With Adverse Drug Reactions (ADRs) Related to Replagal	An ADR is defined as a response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. Number of participants with ADRs will be reported.	From the study drug administration up to Week 53
Primary	Number of Participants With Infusion-related Reactions of Replagal	Number of participants with infusion-related reactions of Replagal will be reported.	From the study drug administration up to Week 53
Primary	Number of Participants With Death	Number of participants with deaths related to Replagal will be reported.	From the study drug administration up to Week 53
Secondary	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)	Change in eGRF levels will be assessed from baseline up to week 53.	Baseline and at Weeks 13, 27, 39, and 53
Secondary	Number of Participants With Change in Frequency and Regimen of Analgesic use of Replagal for Neuropathic Pain	Participants who are already taking analgesics, any change in frequency and regimen of analgesic use will be monitored throughout the study. Number of participants with change in frequency and regimen of analgesic use of Replagal for neuropathic pain will be reported.	Baseline up to Week 53
Secondary	Change From Baseline in Urine Concentration of Globotriaosylceramide (Gb3)	Change from baseline in urine concentration of Gb3 will be assessed.	Baseline and at Weeks 13, 27, 39, and 53
Secondary	Change From Baseline in Urine Protein Creatinine Ratio	Urine protein creatinine ratio will be assessed.	Baseline and at Weeks 13, 27, 39, and 53
Secondary	Percent Change From Baseline in Left Ventricular Mass Index (LVMI)	The 2-dimensional (2D) echocardiogram will be performed within one month of participant enrolment or at the time of screening, Week 27, and Week 53 and the percent change values from baseline in LVMI (gram per meter square [g/m^2]) will be measured and reported.	Baseline and at Weeks 27 and 53
Secondary	Percent Change From Baseline in Left Ventricular Wall Thickness	The 2D echocardiogram will be performed within one month of participant enrolment or at the time of screening, Week 27, and Week 53 and the percent change values from baseline in left ventricular muscular thickness will be measured and reported.	Baseline and at Weeks 27 and 53
Secondary	Percent Change From Baseline in Ejection Fraction	The 2D echocardiogram will be performed within one month of participant enrolment or at the time of screening, Week 27, and Week 53 and the percent change values from baseline in ejection fraction will be measured and reported.	Baseline and at Weeks 27 and 53
Secondary	Percent Change From Baseline in Quality of Life Based on Questionnaire 36-itme Form Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores)	SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. SF-36 consist of 36 items that are aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time: to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]). Four domains comprised physical component summary (PCS) score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised mental component summary (MCS) score (vitality, social functioning, role-emotional, mental health). The scores ranges from 0 to 100. Higher scores indicating better HRQL.	Baseline and at Weeks 27 and 53

External Links

•   To obtain more information on the study, click here/on this link